Skip to main content

Table 2 Primary treatment outcomes

From: A randomized trial on effectiveness of artemether-lumefantrine versus artesunate plus amodiaquine for unsupervised treatment of uncomplicated Plasmodium falciparum malaria in Ghanaian children

 

Treatment

  

Outcome

ASAQ

AL

Hazard ratio

(95% CI)

p valuea

Per protocol b

n = 96

n = 103

  

Recurrent parasitaemia

15 (15.6%)

23 (22.3%)

1.49 (0.77–2.87)

0.233

Recurrent parasitaemia (PCR corrected)

7 (7.3%)

12 (11.7%)

1.71 (0.67–4.38)

0.265

ETF

0

0

  

LCF

7 (7.3%)

18 (17.5%)

2.41 (1.003–5.79)

0.049

LCF (PCR corrected)

3 (3.1%)

10 (9.7%)

3.25 (0.89–11.92)

0.075

LPF

8 (8.3%)

5 (4.9%)

0.64 (0.21–1.99)

0.443

LPF (PCR corrected)

4 (4.2%)

2 (1.9%)

0.52 (0.09–2.87)

0.452

ACPR

81 (84.4%)

80 (77.7%)

0.96 (0.70–1.31)

0.792

ACPR (PCR corrected)

88 (91.7%)

91 (88.3%)

1 (0.74–1.34)

0.986

Intention to treat c

n = 108

n = 109

  

Recurrent parasitaemia

15 (13.9%)

23 (21.1%)

1.51 (0.78–2.90)

0.218

Recurrent parasitaemia (PCR corrected)

7 (6.5%)

12 (11.0%)

1.72 (0.67–4.41)

0.256

ETF

0

0

  

LCF

7 (6.5%)

18 (16.5%)

2.44 (1.02–5.85)

0.046

LCF (PCR corrected)

3 (2.8%)

10 (9.2%)

3.27 (0.89–11.96)

0.073

LPF

8 (7.4%)

5 (4.6%)

0.66 (0.21–2.04)

0.409

LPF (PCR corrected)

4 (3.7%)

2 (1.8%)

0.53 (0.10–2.94)

0.468

ACPR

88 (81.5%)

86 (78.9%)

0.96 (0.71–1.30)

0.813

ACPR (PCR corrected)

95 (88.0%)

97 (89.0%)

1.00 (0.75–1.33)

0.988

  1. Please note:
  2. a Tested by Cox regression.
  3. b Included were all patients who matched the inclusion criteria without violating the protocol.
  4. c Included were all patients who matched all inclusion criteria without repeated vomiting after the first study drug administration.
  5. CI, convidence interval; ASAQ, artesunate plus amodiaquine; AL, artemether-lumefantrine; ETF, early treatment failure; LCF, late clinical failure; LPF, late parasitological failure; ACPR, adequate clinical and parasitological response